期刊
JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY
卷 32, 期 6, 页码 648-650出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jpag.2019.07.003
关键词
CLOVES syndrome; PROS; Alpelisib; BYL719
Background: Most patients with phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA)-related overgrowth spectrum become symptomatic early in life and need treatment before puberty. Recently, the specific inhibition of PIK3CA pathways has been proposed as a therapeutic option for these patients improving their surgical options and quality of life. Alpelisib, a specific alpha fraction inhibitor, has shown promising results. Case: A 17-year-old girl presented with severe involvement of her external genitalia with a combined vascular malformation in the context of congenital, lipomatous, overgrowth, vascular malformations, epidermal nevi and spinal/skeletal anomalies and/or scoliosis syndrome, needing frequent blood transfusions for anemia due to vaginal bleeding and use of a crutch for walking. After failure of treatment with rapamycin, compassionate treatment with alpelisib was started with excellent response. Summary and Conclusion: PIK3CA inhibitors might become a new option of treatment for PIK3CA-related overgrowth spectrum patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据